Use financial incentives to end drug shortages; Bay State drugmakers are hiring;

> Lack of financial incentives trumps capacity constraints in ongoing generic cancer drug shortages. Story

> Gasp! Some Boston-area drugmakers plan to boost their workforces by 5 percent to 10 percent, but it's taking them a long time to fill open positions, says a federal report. Story

> CMO Lonza is investing $12 million to expand its biopharmaceutical development services platform in Singapore. Item

> Hovione and Particle Sciences are targeting poorly water soluble drugs in a collaboration to provide drug development services. Article

> SGS North America is now ISTA-certified for thermal testing on insulated shipping containers used for temperature-sensitive products. Release

> Unimpeded by the recent warning letter issued for its California manufacturing plant, Impax is planning a$52-million expansion of production capacity at its Taiwan facility. Item

> Biologics services provider Omnia has unveiled spraying drying services for drug stabilization. Omnia release

> SAFC and Pfenex have teamed to produce therapeutic proteins and vaccine components. Story

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.